Precision Phage Therapy in the Post-Antibiotic Era: From Phage Genomics to Clinical Translation against Multidrug-Resistant Bacteria
Microbiology Archives: An International Journal · 06.09.2026 · 8 (2) · 101-115
DOI: 10.51470/ma.2026.8.2.101 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Archives: An International Journal, online erschienen am 11.10.2026. Verfasst von Bhanupratap Vishwakarma und 6 weiteren Autor:innen.
Abstract (Originalsprache)
The growing prevalence of antimicrobial resistance (AMR) has become a major global health concern, reducing the effectiveness of conventional antibiotics against multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacterial pathogens. This has renewed interest in bacteriophages as alternative and complementary antimicrobial agents. Phages exhibit specific interactions with bacterial hosts, replicate within susceptible cells and cause bacterial lysis through mechanisms distinct from those of antibiotics. Their host specificity offers the potential to target pathogenic bacteria while minimizing disruption to beneficial microbiota. Advances in whole-genome sequencing, comparative genomics and computational microbiology have improved the identification and characterization of therapeutic phages, enabling the selection of strictly lytic candidates and the exclusion of those carrying undesirable virulence, antimicrobial resistance and lysogeny-associated genes. Molecular characterization, host-range prediction, machine learning and analysis of bacterial antiphage defence systems are further supporting more informed phage selection and therapeutic design. Recent developments in genetic engineering, directed evolution and CRISPR-based technologies have expanded the potential applications of phages, including host-range modification, disruption of bacterial defence mechanisms and targeted antibacterial activity. Phages may also influence bacterial evolution by selecting resistance-associated mutations that reduce virulence, impair biofilm formation or restore susceptibility to certain antibiotics. Phage–antibiotic combinations have shown enhanced antibacterial activity under specific conditions, while compassionate-use cases and emerging clinical studies have demonstrated potential benefits in selected difficult-to-treat infections. However, clinical translation remains limited by challenges involving phage susceptibility testing, pharmacokinetics, dosing, immune responses, bacterial resistance, manufacturing consistency and regulatory standardization. This review examines advances in precision bacteriophage therapy, with particular emphasis on phage genomics, host-range determination, rational cocktail design, engineered phages, biofilm targeting, evolutionary steering, artificial intelligence-assisted selection and clinical translation. Integrating genomic information, computational tools and individualized microbiological assessment may help establish bacteriophage therapy as a more targeted and adaptive approach to managing drug-resistant bacterial infections.
Zitieren
APA
Vishwakarma, B., Rupani, J., Sharma, V., Das, P., Yadav, T., Bhusate, G., & Mishra, S. (2026). Precision Phage Therapy in the Post-Antibiotic Era: From Phage Genomics to Clinical Translation against Multidrug-Resistant Bacteria. Microbiology Archives: An International Journal, 8(2), 101-115. https://doi.org/10.51470/ma.2026.8.2.101
Vancouver
Vishwakarma B, Rupani J, Sharma V, Das P, Yadav T, Bhusate G, et al. Precision Phage Therapy in the Post-Antibiotic Era: From Phage Genomics to Clinical Translation against Multidrug-Resistant Bacteria. Microbiology Archives: An International Journal. 2026;8(2):101-115. doi:10.51470/ma.2026.8.2.101
BibTeX
@article{Vishwakarma2026,
author = {Vishwakarma, Bhanupratap and Rupani, Jinkal and Sharma, Vishal and Das, Pujita and Yadav, Tanvi and Bhusate, Gauri and Mishra, Sneha},
title = {Precision Phage Therapy in the Post-Antibiotic Era: From Phage Genomics to Clinical Translation against Multidrug-Resistant Bacteria},
journal = {Microbiology Archives: An International Journal},
year = {2026},
volume = {8},
number = {2},
pages = {101--115},
doi = {10.51470/ma.2026.8.2.101}
}
EUVIMED